Characterization of Hematopoietic Stem Cells
- 1 December 1995
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 770 (1 Bone Mar) , 42-52
- https://doi.org/10.1111/j.1749-6632.1995.tb31042.x
Abstract
On the basis of density-separated mononuclear cells isolated from bone marrow, peripheral blood, and cord blood, we have repeatedly shown good correlation between two-color flow cytometric (FACS) CD34 analysis and colony formation in the clonogenic assay. We have analyzed the distributions of CD34 subpopulations in these three stem cell sources using patients' and donors' bone marrow biopsies (n = 196), cord blood samples from full-term deliveries (n = 14), and peripheral blood from patients mobilized by chemotherapy and/or cytokine treatment (n = 258). Irrespective of absolute cell counts, the mean (+/- SD) proportions of CD34+ cells were clearly higher in bone marrow (5.6 +/- 4.6% of mononuclear cells) than in peripheral blood (1.9 +/- 2.6) and cord blood (1.7 +/- 2.6). However, two-color FACS analyses revealed significant differences among these cell sources with regard to their distribution of CD34 subpopulations: B-cell progenitors coexpressing CD34 and CD19, at considerable concentrations of > 0.5%, were only found in bone marrow (mean 30 +/- 24.3% of CD34+ mononuclear cells, median 28.7%, minimum 0%, maximum 83.3%). In addition, CD34+ cells in S/G2M phase were never detected in peripheral blood or cord blood, but only in bone marrow at a concentration of 10-15% of CD34+ mononuclear cells. On the other hand, the proportions of relatively immature myeloid progenitors, as characterized by not expressing CD45RA and by higher clonogenic capacity, were significantly higher in cord blood (76.7 +/- 17.2) and peripheral blood (58.2 +/- 17.5) than in bone marrow (26.4 +/- 16.7). These data were confirmed by analysis of apheresis products and of progenitors positively selected from different cell sources, and they may explain why, in autologous transplantations of analogous amounts of CD34+ cells, peripheral blood is superior to bone marrow. We conclude from our results that if successful transplantation and timely recovery depend on the number of CD34+ cells transplanted, the mean amount of stem cells required is 1.4- (for myeloid cells) or 2.2-fold (for early myeloid cells) higher for bone marrow than for peripheral blood.Keywords
This publication has 11 references indexed in Scilit:
- A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cellsBlood, 1994
- ISHAGE—Teacher's PetJournal of Hematotherapy, 1994
- Comparison of the Phenotype and Clonogenicity of Normal CD34+Cells from Umbilical Cord Blood, Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood, and Adult Human Bone MarrowJournal of Hematotherapy, 1994
- Does Cord Blood Contain Enough Progenitor Cells for Transplantation?Journal of Hematotherapy, 1994
- Commentary: Prospects for Standardization of Stem Cell Determination within EuropeJournal of Hematotherapy, 1993
- Use of Flow Cytometric CD34 Analysis to Quantify Hematopoietic Progenitor CellsLeukemia & Lymphoma, 1993
- Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancerBlood, 1992
- Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapyThe Lancet, 1992
- Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometryBlood, 1991
- Peripheral Blood Stem Cell Autografts in Children with Acute Lymphoblastic Leukemia and Lymphoma: Updated ExperienceLeukemia & Lymphoma, 1991